Barr Laboratories and Galen Holdings acquired rights to trade and market number of women’s healthcare products. Barr will acquire exclusive rights in US and Canada for Loestrin® and Loestrin® FE oral contraceptives from Galen and also a non-exclusive license to launch generic versions of Galen's femhrt hormone therapy and Estrostep® oral contraceptive products.